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Background/Aims: Abdominal ultrasonography is useful for the detection and diagnosis of nonalcoholic fatty liver disease 
(NAFLD). The aims of this study were to establish a predictive model for the selection of subjects for abdominal ultrasonography 
for the diagnosis of NAFLD and to assess validity of the model. Methods: The subjects included 901 people who visited the 
health examination center of the Busan Medical Center. We conducted multiple logistic regression analyses of potential risk 
factors to identify independent risk factors for NAFLD, and developed an index system. Results: Four independent risk factors 
were identified. The index system was developed by assigning 1 clinical scoring point to approximately 0.7 logistic regression 
coefficients to each factor as follows: alanine aminotransferase/aspartate aminotransferase ratio >1.5 (odds ratio [OR], 2.22; 
95% confidence interval [CI], 1.21-4.07; P=0.010), 1 point; γ-glutamyl transpeptidase >50 (OR, 2.15; 95% CI, 1.13-4.07; 
P=0.019), 1 point; triglyceride >150 mg/dL (OR, 1.92; 95% CI, 1.14-3.24; P=0.015), 1 point; 23 kg/m
2≤BMI<25 kg/m
2 (OR, 3.68; 
95% CI, 2.05-6.63; P<0.001), 2 points; and BMI 25 kg/m
2 (OR, 7.65; 95% CI, 4.29-13.62; P<0.001), 3 points. The area under the 
receiver operating characteristics curve was 0.797 (95% CI, 0.751-0.842), and when 3 points was used as a cut-off value, the 
sensitivity and specificity were 71.7% and 75.9%, respectively. Conclusions: NAFLD can be predicted through the clinical application 
of the index system established herein. If abdominal ultrasonography is used for high-risk patients, NAFLD will be diagnosed and 
managed in its early stage. (Korean J Hepatol 2011;17:19-26)
Keywords: Nonalcoholic fatty liver disease; Diagnosis; Ultrasonography
Received April 28, 2010; Revised September 6, 2010; Accepted December 9, 2010
Abbreviations: AFP, α -fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under 
the curve; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HbA1C, hemoglobin A1C; HBsAg, hepatitis B surface antigen; 
HCV, hepatitis C virus; HDL-C, high-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; ROC, receiver operating 
characteristics; SBP, systolic blood pressure; γ -GTP,  γ -glutamyl transpeptidase
Corresponding author: Jie Hyang Lim
Department of Family Medicine, Busan Medical Center, 96 Worldcup-gil, Yeonje-gu, Busan 611-072, Korea
Tel. +82-51-607-2185, Fax. +82-51-507-3001, E-mail; hanna6368@empal.com
Copyright Ⓒ  2011  by  The Korean Association for the Study of the Liver
The Korean Journal of Hepatology∙pISSN: 1738-222X eISSN: 2093-8047
INTRODUCTION
Non alcoholic fatty liver disease (NAFLD) is a condition with 
pathological findings similar to those of alcoholic fatty liver dis-
ease in non-drinkers or patients with no history of sufficient 
drinking to cause damage to the liver. NAFLD presents various 
progression ranging from simple steatosis to non alcoholic 
steatohepatitis (NASH) which accompany extensive inflammation 
or fibrosis.
1 The term NASH was first used in 1980 by Ludwig et 
al,
2 who assembled the clinical and pathological characteristics 
of 20 patients with no history of significant drinking enough to 
cause damage to the liver. Since NAFLD has no or non-specific 
clinical symptoms in most cases, it is diagnosed by chance in 
many cases during abdominal ultrasonography.
3 In the West, 
NAFLD is reported to be the most common liver disease, with 
prevalence rates in general populations at 10-24%, and it is 
reported that the prevalence rate reaches 74% in obese 
populations.
4,5 Hepatocellular carcinoma can also develop from 
the progression of fatty liver disease.
6 It is known that NAFLD 
can develop from various causes including drugs, obesity, type 2 
diabetes, and dyslipidemia.
4,7 Recently, the prevalence rate of 
NAFLD has been increasing in Korea as well due to changes in 
life style. Prevalence rate of NAFLD varies among studies but 
has been seen in the range of 18.6-47.3%.
8,9 
Recent study showed that in case of normal findings of labo-
ratory tests and physical examination, only 4.1% of all general 20  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
health examinations result in prognosis improvement and disease 
prevention by routine use of abdominal ultrasonography as a 
screening test.
10 In the aspect of cost-effectiveness, it is consid-
ered desirable to use abdominal ultrasonography only when 
abnormalities are found in laboratory tests or physical examinations. 
Therefore, it is considered, if abdominal ultrasonography is used 
when NAFLD is predicted through laboratory tests and physical 
examination, NAFLD will be early diagnosed, appropriately 
treated, and effectively managed.
The purpose of this study was to establish a predictive model 
to select subjects for abdominal ultrasonography for the diag-
nosis of NAFLD and assess the validity of the model.
PATIENTS AND METHODS
Patients
Subjects of this study included 901 persons who visited the 
Busan Medical Center between July 2007 and December 2008 
for health examinations. Of the total subjects, seven persons who 
did not undergo abdominal ultrasonography and the first exami-
nation records of 11 persons who underwent health examinations 
twice were excluded. Other exclusions included 66 persons who 
were diagnosed with liver diseases other than fatty liver disease 
in abdominal ultrasonography; 28 patients with positivity of 
HBsAg; 9 patients with positivity of anti-HCV; 203 persons with 
daily alcohol intakes of ≥20 g; and 121 persons with no data on 
alcohol intake. The remaining 456 persons (178 males and 278 
females) were included in the study. Of the 456 persons included, 
145 persons were diagnosed as fatty liver disease by abdominal 
ultrasonography, and they were assigned to a NAFLD group. The 
remaining 311 persons were identified with normal livers, and 
they were assigned to a control group.
Abdominal ultrasonography
Abdominal ultrasonography was conducted by the one radiol-
ogist in all the cases and the degree of fat deposition was divided 
into mild, moderate, and severe. In this study, presence of fatty 
liver disease was used rather than its severity.
Data collection
Alcohol intake was examined for the amount of drinking per 
time and the number of times of drinking per week through 
inquiries. Daily alcohol intake was calculated by converting 
alcohol per one bottle of soju (most popular Korean liquor) into 
approximately 70 g. Weights and heights were measured using 
an obesity-measuring device (DS-102, DSJenix Co., Ltd, Seoul, 
Korea) and body mass index (BMI) was calculated by dividing 
measured weights (kg) by the square of heights (m
2). Waist cir-
cumferences were obtained by measuring the area in the halfway 
point between the lowest part of the ribs and the iliac crest in a 
standing position after a maximum expiration. Blood pressure 
was measured on the right upper arm using an electronic blood 
pressure manometer (Easy X800, Jawon Medical Co., Ltd., 
Gyeongsan, Korea) at a sitting position after being in a resting 
state for at least 10 minutes, and if the resting blood pressure of a 
person was 140/90 mmHg or higher, blood pressure was 
measured two times and the average value was recorded. 
Hypertension was diagnosed in patients who were taking drugs 
for hypertension, had been previously diagnosed with hyper-
tension, or had blood pressure ≥140/90 mmHg. Diabetes was 
diagnosed in patients who were taking drugs for diabetes, had 
been previously diagnosed with diabetes, or had hemoglobin 
A1C (HbA1C) values ≥6.5%.
11 Blood was collected in the morn-
ing after a 12-hour fast for biochemical tests. Total bilirubin, 
direct bilirubin, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl 
transpeptidase (γ-GTP), total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), triglyceride, fasting glucose, HbA1C, 
α-fetoprotein (AFP), serum ferritin, and ALT/AST ratio were 
analyzed. 
Statistical analysis
Collected data were statistically analyzed by SPSS Ver. 13 
(SPSS, Inc., Chicago, USA) for Windows. The study subjects 
were divided into a NAFLD group and a control group. 
Independent sample t-tests were conducted with age, daily alco-
hol intake, total bilirubin, direct bilirubin, AST, ALT, ALT/AST 
ratio, ALP, γ-GTP, total cholesterol, HDL-C, triglyceride, fasting 
glucose, HbA1C, AFP, serum ferritin, BMI, waist circumference, 
systolic blood pressure (SBP), and diastolic blood pressure 
(DBP), and the values were presented as mean±standard 
deviation. Chi-square tests were conducted with sex, hyper-
tension and diabetes. Simple logistic regression analyses were 
conducted with variables that had statistically significant differ-
ences at significance levels <0.05 in the t-tests and the chi-square 
tests. Multiple logistic regression analyses were conducted to 
identify independent risk factors of NAFLD with variables that Young Jin Park, et al. Simple index system to predict NAFLD  21
Table 1. Comparison of baseline characteristics between the control and nonalcoholic fatty liver disease (NAFLD) groups
Characteristics
* Control group (n=311) NAFLD group (n=145) P-value
†
Age (years) 44.9±11.8 47.6±10.8 0.017
Male (n, %) 96 (30.9) 82 (56.6) <0.001
Alcohol intake (g/day) 1.90±4.11 2.64±4.66 0.089
Hypertension (n, %) 53 (17.0) 39 (26.9) 0.015
Diabetes (n, %) 13 (4.2) 14 (9.7) 0.021
Total bilirubin (mg/dL) 0.98±0.43 0.93±0.35 0.201
Direct bilirubin (mg/dL) 0.23±0.19 0.22±0.10 0.264
AST (IU/L) 25.8±22.1 28.5±12.6 0.091
ALT (IU/L) 26.4±16.5 39.8±28.2 <0.001
ALT/AST ratio 1.07±0.37 1.35±0.44 <0.001
ALP (IU/L) 58.4±19.2 64.3±18.8 0.002
γ-GTP (IU/L) 23.5±25.6 42.9±35.4 <0.001
Total cholesterol (mg/dL) 183.1±33.2 196.6±37.2 <0.001
HDL cholesterol (mg/dL) 46.7±14.4 39.9±11.4 <0.001
Triglyceride (mg/dL) 106.1±63.0 155.9±79.5 <0.001
Fasting glucose (mg/dL) 98.0±22.3 102.4±19.4 0.033
HbA1C (%) [266, 124] 5.60±0.97 5.75±0.56 0.054
AFP (μg/L) 4.28±19.74 3.37±1.98 0.421
Serum ferritin (μg/L) [266, 124] 64.4±63.0 95.3±73.4 <0.001
BMI (kg/m
2) 22.2±2.7 25.4±3.0 <0.001
Waist circumference (cm) [268, 130] 77.4±8.6 87.3±8.7 <0.001
SBP (mmHg) 119.7±16.5 126.7±16.9 <0.001
DBP (mmHg) 73.2±10.3 78.0±10.2 <0.001
Values are expressed as mean ± standard deviation or n (%).
*  Numbers in square brackets indicate number of patients for whom data were missing [control, NAFLD].
†  P-value by independent sample t-tests (continuous variables) or chi-square tests (categorical variables). 
NAFLD, nonalcoholic fatty liver disease; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; 
γ-GTP,  γ-glutamyl transpeptidase; HDL, high density lipoprotein; HbA1C, hemoglobin A1C; AFP, α-fetoprotein; BMI, body mass 
index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
had statistically significant differences at significance levels 
<0.05 in the simple logistic regression analyses. Then, we assigned 
clinical scores in integers to logistic regression coefficients 
obtained multiple logistic regression analyses, thereby induced 
the index system. The index system was applied to the study 
groups to assess the validity of the index system. All of the stat-
istical analyses were conducted with two-tailed tests and statisti-
cally significant levels were determined as being <0.05.
RESULTS
Prevalence rate of NAFLD
Of the total 456 study subjects, 178 (39.0%) were males and 
278 (61.0%) were females, and their average age was 45.8 ± 11.5 
years. Since all the subjects were identified as consuming <20 g 
of alcohol a day, the 145 (31.8%) subjects who were diagnosed 
with fatty liver disease on abdominal ultrasonography were diag-
nosed as NAFLD. A total of 82 (46.1%) males and 63 (22.7%) 
females were diagnosed as NAFLD. 
Clinical characteristics of the NAFLD group
The mean age of the NAFLD disease group was 47.6 years 
which was higher than that of the control group, which was 44.9 
±11.8 years (P=0.017). There were 82 (56.6%) males in the 
NAFLD group, which was more than that of the control group 
(56.6 vs. 30.9%, P<0.001). The mean BMI and waist circum-
ference were higher in the NAFLD group than in the control 
group. SBP, DBP, and ratios of hypertension patients were also 22  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 2. Results of univariate analyses for predictors of NAFLD
Patient characteristics
No. (%) of control 
group
No. (%) of NAFLD 
group
Logistic regression 
coefficients
Odds ratio (95% CI) P-value
*
Age
  -64.9 289 (92.9) 135 (93.1)
  65- 22 (7.1) 10 (6.9) -0.03 0.97 (0.45-2.11) 0.973
Sex
  Women 215 (69.1) 63 (43.4)
  Men 96 (30.9) 82 (56.6) 1.07 2.92 (1.94-4.38) <0.001
Hypertension
  No 258 (83.0) 106 (73.1)
  Yes 53 (17.0) 39 (26.9) 0.58 1.79 (1.12-2.87) 0.015
Diabetes
  No 298 (95.8) 131 (90.3)
  Yes 13 (4.2) 14 (9.7) 0.90 2.45 (1.12-5.36) 0.025
ALT (IU/L)
  -40 277 (89.1) 104 (71.7)
  41- 34 (10.9) 41 (28.3) 1.17 3.21 (1.93-5.34) <0.001
ALT/AST
  -1.5 281 (90.4) 103 (71.0)
  1.51- 30 (9.6) 42 (29.0) 1.34 3.82 (2.27-6.43) <0.001
ALP (IU/L)
  -100 305 (98.1) 137 (94.5)
  101- 6 (1.9) 8 (5.5) 1.09 2.97 (1.01-8.72) 0.048
γ-GTP (IU/L)
  -50 289 (92.9) 101 (69.7)
  51- 22 (7.1) 44 (30.3) 1.74 5.72 (3.27-10.02) <0.001
Total cholesterol (mg/dL)
  -200 217 (69.8) 81 (55.9)
  201-  94 (30.2) 64 (44.1) 0.60 1.82 (1.21-2.74) 0.004
HDL cholesterol (mg/dL)
  40-  93 (29.9) 76 (52.4)
  -39 218 (70.1) 69 (47.6) -0.95 0.39 (0.26-0.58) <0.001
Triglyceride (mg/dL)
  -150 263 (84.6) 83 (57.2)
  151- 48 (15.4) 62 (42.8) 1.41 4.09 (2.61-6.42) <0.001
Fasting glucose (μg/L)
  -99 220 (70.7) 79 (54.5)
  100-  91 (29.3) 66 (45.5) 0.70 2.02 (1.34-3.04) 0.001
Serum ferritin (μg/L)
  -250 261 (98.1) 117 (94.4)
  251-  5 (1.9) 7 (5.6) 1.14 3.12 (0.97-10.04) 0.056
BMI (kg/m
2)
  -22.9 197 (63.3) 26 (17.9)
  23-24.9 65 (20.9) 42 (29.0) 1.59 4.90 (2.79-8.60) <0.001
  25- 49 (15.8) 77 (53.1) 2.48 11.90 (6.91-20.51) <0.001
Waist circumference (cm)
  -79.9 161 (60.1) 27 (20.8)
  80-89.9 81 (30.2) 49 (37.7) 1.28 3.61 (2.10-6.19) <0.001
  90-99.9 25 (9.3) 46 (35.4) 2.40 10.97 (5.81-20.71) <0.001
  100- 1 (0.4) 8 (6.2) 3.87 47.70 (5.74-396.80) <0.001
SBP (mmHg)
  -139 273 (87.8) 119 (82.1)
  140- 38 (12.2) 26 (17.9) 0.45 1.57 (0.91-2.70) 0.104
DBP (mmHg)
  -89 291 (93.6) 128 (88.3)
  90- 20 (6.4) 17 (11.7) 0.66 1.93 (0.98-3.81) 0.057
Data are calculated using univariate logistic regression analyses.
* P-values refer to the difference in diagnosis of NAFLD between subgroups.
NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, 
alkaline phosphatase; γ-GTP, γ-glutamyl transpeptidase; HDL, high density lipoprotein; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure.Young Jin Park, et al. Simple index system to predict NAFLD  23
Table 3. Adjusted odds ratios and clinical scores for predictors of NAFLD
Variable Logistic regression coefficients Adjusted odds ratio (95% CI) P-value Clinical score
*
ALT/AST ratio>1.5 0.80 2.22 (1.21-4.07) 0.010 +1
γ-GTP (IU/L)>50 0.76 2.15 (1.13-4.07) 0.019 +1
Triglyceride (mg/dL)>150 0.65 1.92 (1.14-3.24) 0.015 +1
BMI (kg/m
2)
  23-24.9 1.30 3.68 (2.05-6.63) <0.001 +2
  25- 2.03  7.65 (4.29-13.62) <0.001 +3
Data are calculated using multiple logistic regression analyses. 
* Clinical score was assigned 1 point to around 0.7 of logistic regression coefficients.
NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
γ-GTP,  γ-glutamyl transpeptidase; BMI, body mass index.
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Figure 1. The receiver operating characteristics (ROC) curve of 
the index system developed for the prediction of nonalcoholic 
fatty liver disease. The area under the ROC curve is 0.797 (95% 
confidence interval, 0.751-0.842), and when 3 points is used as a 
cut-off value, the sensitivity and specificity are 71.7% and 75.9%,
respectively.
higher in the NAFLD group. Although the prevalence of diabetes 
mellitus and fasting glucose were higher in the NAFLD group, 
HbA1C had no significant difference between the two groups. 
AST had not significantly different between the two groups 
while ALT, ALT/AST ratio, ALP, γ-GTP, total cholesterol, trigly-
ceride, and serum ferritin were higher in the NAFLD group, but 
HDL-C was lower in the NAFLD group than in the control group 
(Table 1).
Index system using NAFLD-related predictive 
factors
The relative risk factors of NAFLD were examined by con-
ducting simple logistic regression analyses for factors that had 
statistically significant differences between the NAFLD group 
and the control group in Table 1. Except for age, serum ferritin, 
SBP, and DBP, all variables were significantly increased in the 
relative risk of NAFLD (Table 2). Multiple logistic regression 
analyses were conducted using the factors that had significantly 
increased relative risks in the simple logistic regression analyses. 
Based on the results, four independent risk factors (ALT/AST 
ratio, γ-GTP, triglyceride, BMI) of NAFLD were identified. In 
order to induce the index system using the results of the multiple 
logistic regression analyses, clinical scores in integers were 
given to logistic regression coefficients. By giving 1 point of 
clinical score to around 0.7 of logistic regression coefficients, the 
index system ranged from 0 point at the minimum to 6 points at 
the maximum. The points was given to each factor as follows: 
ALT/AST ratio > 1.5 (OR, 2.22; 95% CI, 1.21-4.07; P=0.010), 
1 point; γ-GTP > 50 (OR, 2.15; 95% CI, 1.13-4.07; P=0.019), 
1 point; triglyceride > 150 mg/dL (OR, 1.92; 95% CI, 1.14-3.24; 
P=0.015), 1 point; 23 kg/m
2 ≤ BMI < 25 kg/m
2 (OR, 3.68; 95% 
CI, 2.05-6.63; P< 0.001), 2 points; and 25 kg/m
2 ≤BMI (OR, 
7.65; 95% CI, 4.29-13.62; P<0.001), 3 points (Table 3).
Validity of the index system for NAFLD
To assess the validity of the induced index system, we applied 
it to the relevant study groups and obtained its ROC curve 
(Fig. 1), sensitivity, specificity, positive predictive value, and 
negative predictive value (Table 4). The AUC of the ROC curve 
was 0.797 (95% CI: 0.751-0.842); when 3 points were used as a 
cut-off value, sensitivity was 71.7% and specificity was 75.9%; 
when 4 points were used as a cut-off value, sensitivity was 
reduced to 46.9%, specificity increased to 92.3%, the positive 
predictive value was 73.9%, and the negative predictive value 
was 78.8%.24  The Korean Journal of Hepatology Vol. 17. No. 1, March 2011
Table 4. Accuracy of the index system for the prediction of NAFLD
Index system
* No. of patients (%)
n=456
No. of NAFLD (%)
n=145
Sensitivity (%) Specificity (%) Positive predictive 
value (%)
Negative  predictive 
value (%)
0 183 (40.1) 19 (13.1) 100  0.0 31.8 -
1 31 (6.8) 6 (4.1) 86.9 52.7 46.2 89.6
2 63 (13.8) 16 (11.0) 82.8 60.8 49.6 88.3
3 87 (19.1) 36 (24.8) 71.7 75.9 58.1 85.2
4 53 (11.6) 36 (24.8) 46.9 92.3 73.9 78.8
5 24 (5.3) 19 (13.1) 22.1 97.7 82.1 72.9
6 15 (3.3) 13 (9.0)  9.0 99.4 86.7 70.1
*  The index system was induced by assigning 1 clinical score point to around 0.7 of logistic regression coefficients, and the index 
system ranged from 0 point at the minimum to 6 points at the maximum.
NAFLD, nonalcoholic fatty liver disease.
DISCUSSION
NAFLD is one of the most common liver diseases, not only in 
the West but also in Korea.
4,5,8,9 Prevalence rate of NAFLD is 
also gradually increasing. In addition, most patients with 
NAFLD do not know that they have the disease or live without 
any treatment even after diagnosis since they have no symptoms. 
However, since NAFLD can develop into liver cirrhosis or even 
hepatocellular carcinoma, it should be detected early and man-
aged appropriately.
1,6,7 
The prevalence rate of NAFLD diagnosed by abdominal ultra-
sonography in Korea was surveyed to be 19.9% in 1994.
12 The 
prevalence rate of NAFLD is further increased, as obese pop-
ulations has been increased along with changes in life styles. 
Recently, prevalence rates of NAFLD is surveyed in the range of 
18.6-47.3%.
8,9 In this study, of the 456 study subjects, 145 
(31.8%) study subjects were diagnosed as NAFLD; thus, the 
prevalence rate did not differ from the results of previous studies 
in Korea but was higher than the results of studies of NAFLD 
prevalence rate in the West (10-24%).
4
In this study, four independent risk factors (ALT/AST ratio, γ- 
GTP, triglyceride, and BMI) were identified. Compared to the 
known risk factors of NAFLD which are obesity, diabetes, and 
dyslipidemia, the factors were consistent with the results of this 
study except for diabetes. ALT which is a finding that can in-
dicate NAFLD in blood tests was also consistent with the result 
(ALT/AST ratio) of this study.
4,13 In this study as well, the preva-
lence of diabetes was significantly different between the 2 
groups (4.2% in the control group and 9.7% in the NAFLD 
group), but it was not an independent risk factor. This is thought 
to be due to the fact that the number of subjects in the study 
groups was small. Alcohol intake was limited to <20 g per day, 
but increased γ-GTP was identified as an independent risk factor 
of NAFLD. That can be thought that even low alcohol intake is a 
risk factor of fatty liver disease. However, various cross-sec-
tional studies were presented that γ-GTP increases is associated 
with insulin resistance or metabolic syndrome.
14,15
Harrison et al
16 proposed a scoring system that was intended to 
diagnose and treat patients with NAFLD who also had fibrosis 
with at least mild degree. In that study, the scoring system ranged 
from 0 point to 4 points. The points was given to each factor as 
follows: BMI ≥28 kg/m
2, 1 point; AST/ALT ratio ≥0.8, 2 points; 
and if diabetes mellitus, 1 point. Cases with ≥2 points was asso-
ciated with an odds ratio for advanced fibrosis of 17 and a neg-
ative predictive value of 96%. However, in that study, the scoring 
system was focused on fibrosis rather than diagnosis of NAFLD 
and used liver biopsy instead of ultrasonography for diagnosis of 
fibrosis.
Lee et al
17 derived a formula as a screening tool for 
NAFLD that can be utilized for selecting individuals for 
liver ultrasonography. The formula was derived using a 
logistic regression model: hepatic steatosis index (HSI) = 8× 
(ALT/AST ratio) + BMI (+2, if female; +2, if diabetes mellitus). 
At values of < 30.0 or > 36.0, HSI ruled out NAFLD with a sen-
sitivity of 93.1%, or detected NAFLD with a specificity of 
92.4%, respectively. However, that study also used ultra-
sonography instead of liver biopsy for diagnosis of steatosis, and 
the accuracy of the diagnosis in that study was similar to that in 
this study despite difference of variables and complex formula.
This study had several limitations. Ultrasonography rather 
than liver biopsy was used for diagnosis of NAFLD. 
Ultrasonography has lower accuracy than liver biopsy.
18 In Young Jin Park, et al. Simple index system to predict NAFLD  25
addition, the role of ultrasonography in the diagnosis of steato-
hepatitis has been identifying the existence and degree of stea-
tosis, but ultrasonography is not effective in differentiating 
between simple steatosis and steatohepatitis.
19 However, since 
steatohepatitic tissue is not evenly distributed across the liver 
parenchyma, findings from liver biopsy of a partial and small 
amount of the liver can not be represented of the entire liver.
20 
On the other hand, ultrasonography has high sensitivity, and it is 
known that the degrees of fat deposition in ultrasonography 
are significantly correlated with that in biopsy. Above all, there 
are many practical restrictions in executing invasive liver biopsy 
in patients with no symptoms; therefore, NAFLD was diagnosed 
by ultrasonography instead of liver biopsy in this study.
18
 The absolute criteria for the permissible alcohol intake in 
diagnosis of NAFLD has not been established. The National 
Institutes of Health (NIH) permits consumption of 140 g of 
alcohol per week for men and 70 g of alcohol per week for 
women. Becker et al
21 reported that the risk of damage to the 
liver would increase if alcohol intake was larger than 168 g per 
week for men and 84 g per week for women; thus, the permitted 
limits in that study are different from those in this study. 
However, in studies conducted in Asian countries, the permis-
sible alcohol intake for NAFLD was presented as 20-30 g per day 
for both men and women.
22-24 In this study as well, the permis-
sible range daily alcohol intake was limited to 20 g for both men 
and women, and there was no statistically significant difference 
in alcohol intake between the NAFLD group and the control 
group.
The index system was not induced based on the association 
between NAFLD and factors known from other studies but rather 
was based on only the statistical results of this study. Subjects 
included only those individuals who visited one health examina-
tion center of a general hospital; thus, the possibility exists that 
many persons with health problems were included in this 
population.
In addition, in case a discrimination tool is developed by using 
logistic regression analyses as the index system in this study, the 
problem of overfitting can occur. Therefore, the developed tool 
should be applied to other groups to calculate sensitivity, specif-
icity, and the AUC of ROC curves. However, the subjects could 
not be divided in this study since the number of study groups was 
small.
Fatty liver of other causes should be excluded to diagnose 
NAFLD. However, due to the retrospective nature of this study 
that analyzed only the data on inquiries and tests of patients, all 
causes of NAFLD could not be excluded. We attempted to 
exclude as many as possible causes by checking all histories and 
excluding all patients with viral hepatitis and otherwise.
Unlike the ALT/AST ratios in this study, AST/ALT ratios is 
usually greater than 2 in cases of alcoholic fatty liver disease, 
thus, they are known to be useful indices for distinguishing alco-
holic fatty liver disease from other diseases.
25 However, for 
NAFLD, ALT values are generally higher than AST values, and 
if ALT/AST ratios >1.5 are converted into reciprocal numbers, 
they will be changed into AST/ALT ratios <0.667, which 
involves inconvenience. Therefore, in this study, AST/ALT 
ratios were changed into ALT/AST ratios. However, since 
ALT/AST ratios can be ≤1.5 in patients who have NAFLD with 
severe progressed fibrosis, severe cases may have lower points 
than mild cases in the index system.
26
If the cut-off value in the index system is determined to be 3 
points, its sensitivity and specificity is higher than 70%; thus, this 
system is considered to be a good tool to predict NAFLD through 
simple blood tests, physical examinations, and outpatient 
inquiries. If the cut-off value is determined to be 4 points, 
although sensitivity is reduced to 46.9%, specificity is increased 
to 92.3%; thus, it is thought that this index system can also be 
used as a tool to strongly recommend abdominal ultrasono-
graphy to patients with scores ≥4 points.
In conclusion, NAFLD can be sufficiently predicted by the 
simple and noninvasive index system induced in this study. By 
executing abdominal ultrasonography early in patients predicted 
with NAFLD, NAFLD will be early diagnosed, appropriately 
treated, and effectively managed.
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